|
Analysts Expect Approval for Regeneron’s Eylea in CRVO Indication
Regeneron Pharmaceutical’s Eylea is expected to win FDA approval later this week or early next week as a treatment for central retinal vein occlusion (CRVO), according to an analyst note from RBC Capital.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives